clinical trial · NCT06458907
A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.
P+F Products + Features USA Inc.·N/A·not yet recruiting·n = 780
Tricuspid Valve DiseaseHeart Valve DiseasesCardiovascular DiseasesHeart FailureTricuspid Valve RegurgitationTricuspid Valve InsufficiencyTricValve SystemOptimal medical therapy
brief summary
Pivotal trial to evaluate the safety and effectiveness of the P\&F TricValve® Transcatheter Bicaval Valve System.
started
Aug 1, 2026
primary completion
Nov 1, 2028
completion
Nov 1, 2032
last updated
Jul 9, 2026
detailed description
The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TricValve System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with severe tricuspid regurgitation and unsuitable for approved transcatheter therapies. Subjects will be followed at discharge, 1 month, 30 days, 3 months, 6 months 12 months, and annually up to 5 years.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol